Bookbot

IARC Scientific Publications - 154: Biomarkers in Cancer Chemoprevention

Maggiori informazioni sul libro

The evaluation of potential cancer chemopreventive agents require large, long-term, randomized trials in humans. Biomarkers that would allow the identification of subjects exposed to carcinogenic agents, or of individuals genetically, susceptible to cancer would be of great value. This volume is the product of an attempt to assess current knowledge and experience with the use of biomarkers in cancer chemoprevention. It comprises an expert report on the current state of the art use of biomarkers in cancer chemoprevention, introductory sections covering general topics in cancer chemoprevention, and contributions, directed to biomarkers of exposure, intermediate effect and susceptibility relating to six major cancer sites: skin, colorectum, breast, prostate, liver, and upper aerodigestive tract.

Acquisto del libro

IARC Scientific Publications - 154: Biomarkers in Cancer Chemoprevention, Anthony B. Miller, Hella Bartsch, Paolo Boffetta, L Dragsted, H. Vainio

Lingua
Pubblicato
2001
product-detail.submit-box.info.binding
(In brossura),
Condizioni del libro
Danneggiato
Prezzo
20,52 €

Metodi di pagamento

Titolo
IARC Scientific Publications - 154: Biomarkers in Cancer Chemoprevention
Lingua
Inglese
Pubblicato
2001
Formato
In brossura
Pagine
304
ISBN10
9283221540
ISBN13
9789283221548
Serie
Descrizione
The evaluation of potential cancer chemopreventive agents require large, long-term, randomized trials in humans. Biomarkers that would allow the identification of subjects exposed to carcinogenic agents, or of individuals genetically, susceptible to cancer would be of great value. This volume is the product of an attempt to assess current knowledge and experience with the use of biomarkers in cancer chemoprevention. It comprises an expert report on the current state of the art use of biomarkers in cancer chemoprevention, introductory sections covering general topics in cancer chemoprevention, and contributions, directed to biomarkers of exposure, intermediate effect and susceptibility relating to six major cancer sites: skin, colorectum, breast, prostate, liver, and upper aerodigestive tract.